In-PharmaTechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from Glide, BASF and Pall.
We kick off this week’s People On the Move with news that Glide Pharma has appointed Dr. Mark Carnegie-Brown as its Chief Executive Officer (CEO).
Carnegie-Brown comes to Glide from being CEO of Evolutec and prior to that he was the man at the top of pharma and capsule CMO Aenova
The new CEO said: “Having recently completed a successful major fundraising and received significant funding from the UK government-backed Biomedical Catalyst, Glide is well positioned for growth.”
And you can read about that recent cash injection right here .
German chemical giant BASF has added strength to its Asia Pacific team with the appointment of Dr. Albert Heuser as President Greater China and Functions Asia Pacific whilst Gops Pillay assumes the role of President South & East Asia, ASEAN, and Australia/New Zealand.
“China accounts for approximately 50 percent of our Asia Pacific business,” said Dr. Martin Brudermüller, Vice Chairman of the Board of Executive Directors of BASF SE, “and the achievements of the team during the past years have been remarkable.”
And evidence of BASF’s Asian pull can be found here in a recent story regarding BASF’s production of Omega-3 for the South Korean market.
Larry Kingsley, President and CEO of Pall Corporation will step into the shoes of Lisa McDermott until a replacement is found for the role of Chief Financial Officer.
Furthermore, Frank Moschella will resume the positions of Corporate Controller and Chief Accounting Officer.
Last year the firm saw a huge boom in its biopharma consumables which you can read about here .
Dr. Ellen Strahlmen has been appointed Chief Medical Officer and Senior Vice President of R&D at medical device behemoth BD.
Since 2008 Strahlmen has been working at GlaxoSmithKline in a similar role and before then she has held executive posts at Merck, Pfizer, Novartis and Bausch & Lomb.
CEO and President Vincent Forlenza said: "She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients."
Read here for more info about BD’s business-bolstering acquisitions passion.
Developer of the BioPump tissue based delivery platform Medgenics has appointed Joseph Grano Jr onto its Board of Directors, filling the space left by Gary Brukardt after his death in 2012.
Currently Chairman and CEO of Centurian Holdings, “his considerable experience and business acumen will be invaluable assets to Medgenics as we develop our proprietary Biopump technology for the sustained production and delivery of therapeutic proteins from the patients’ own dermis,” according to Medgenics CEO Andrew Pearlman.
Biopharmaceutical company Verastem has picked up cofounder of Ceregene and Director of Biogen Dr. Stephen Sherwin and placed him onto its Board of Directors.
“Steve has a wealth of biopharmaceutical and drug development expertise,” said Dr. Christoph Westphal, Chairman and CEO of Verastem. “We have translated Dr. Bob Weinberg's pioneering cancer stem cell research into clinical drug candidates, and Steve’s insights and guidance will be a key to our future success.”
Protein therapeutics development company Neumedicines has appointed David Morash to its newly created role of Chief Financial Officer and given him a space on the Board of Directors.
According to Dr. Lena Basile, President and CEO of Neumedicines, the ex-CFO of ISE Corporation “joins Neumedicines at an important time in our company’s development as we make preparations to initiate clinical testing with HemaMax™ (rHuIL-12) in two cancer indications.”
Dyax will wave a fond farewell to Dr. Ivana Magovcevic-Liebisch after 12 years with the biopharmaceutical company in the role of Executive Vice President, Chief Operating Officer.
She will continue to serve as a consultant to Dyax but leaves to pursue a senior management opportunity at a multinational pharmaceutical company which she will begin at the end of the month, so keep reading this column to find out where!
Finally this week our attention moves to Evonik, the speciality chemical company who has appointed Christian Kullmann as Executive Vice President and head of the company's new General Secretariat.
His previous role of head of Communications/Board Office will be taken by Stefan Haver.
And Evonik is one of the companies giving a featured presentation a special live webinar, the “Bioavailability challenge 2013” a free to ‘attend’ online webinar series on March 20 focused on the difficulties developers face in ensuring their drug candidates are bioavailable.
Our editorial programme will feature contributions from Big Pharma firms Bristol-Myers Squibb (B-MS) and Hoffman La Roche and analysts group Frost & Sullivan will share its overview of the bioavailability services market.
The event will also feature other presentations from scientists from Agere Pharmaceutical, Ashland, BASF, Bend, Dow, Capsugel, and Catalent.
Click here to sign up for the show. See you on March 20.